. 2013 Dec 5;14:270. doi: 10.1186/1471-2369-14-270

Table 2.

Baseline, follow-up and absolute changes (from baseline) for serum creatinine, eGFR, urine NGAL and delta of urine NGAL in each group of all patients (2A), CKD stage III (2B) and CKD stage IV (2C)

2A
Characteristic	All patients
	No CI-AKI	CI-AKI	CI-AKI (S1)	CI-AKI (S2)
	( N = 114)	(N = 16)	(N = 13)	(N = 3)
Serum creatinine (mg/dL)
Baseline	1.4 ± 0.4	2.0 ± 0.6^a	2.0 ± 0.6^a	1.9 ± 0.3^a
Follow-up (48 hr after)	1.3 ± 0.4	3.1 ± 1.1^a	2.7 ± 1.1^a	4.5 ± 0.4^a,b
Absolute change	0.0 ± 0.2	1.1 ± 0.9^a	0.7 ± 0.9^a	2.7 ± 0.6^a,b
eGFR (ml/min)
Baseline	44 ± 16	27 ± 7^a	27 ± 8^a	28 ± 3^a
Follow-up (48 hr after)	45 ± 17	18 ± 6^a	20 ± 6^a	11 ± 2^a,b
Absolute change	1 ± 5	-9 ± 5^a	-7 ± 3^a	-17 ± 2^a,b
Urine NGAL (ng/ml)
Baseline	68 ± 99	144 ± 111^a	154 ± 143^a	113 ± 45^a
3 h	79 ± 102	211 ± 120^a	213 ± 159^a	202 ± 60^a
6 h	93 ± 129	267 ± 153^a	255 ± 191^a	316 ± 86^a
12 h	115 ± 166	277 ± 169^a	256 ± 181^a	352 ± 133^a
18 h	132 ± 175	298 ± 171^a	315 ± 187^a	272 ± 80^a
24 h	122 ± 165	294 ± 162^a	314 ± 173^a	265 ± 52^a
Delta urine NGAL (ng/ml)
0-3 h	10 ± 92	66 ± 78^a	59 ± 81^a	99 ± 61^a
0-6 h	24 ± 110	122 ± 87^a	101 ± 72^a	213 ± 101^a,b
0-12 h	42 ± 158	132 ± 91^a	112 ± 76^a	242 ± 104^a,b
0-18 h	59 ± 142	135 ± 136^a	137 ± 147^a	159 ± 95^a
0-24 h	49 ± 149	149 ± 136^a	160 ± 136^a	151 ± 80^a
2B
Characteristic	CKD stage III
	No CI-AKI)	CI-AKI	CI-AKI (S1)	CI-AKI (S2)
	(N = 90	(N = 10)	(N = 9)	(N = 1)
Serum creatinine (mg/dL)
Baseline	1.3 ± 0.3	1.5 ± 0.5	1.5 ± 0.7	1.6
Follow-up (48 hr after)	1.2 ± 0.3	2.7 ± 1.0^a	2.5 ± 0.9^a	4.6^a,b
Absolute change	-0.1 ± 0.2	1.1 ± 0.8^a	0.9 ± 0.3^a	3.0^a,b
eGFR (ml/min)
Baseline	46 ± 14	44 ± 9	43 ± 9	43
Follow-up (48 hr after)	48 ± 11	22 ± 8^a	24 ± 8^a	14^a,b
Absolute change	1 ± 6	-22 ± 9^a	-18 ± 6^a	-29^a,b
Urine NGAL (ng/ml)
Baseline	61 ± 81	72 ± 45	75 ± 42	98
3 h	75 ± 83	145 ± 73^a	136 ± 72^a	220^a
6 h	84 ± 119	171 ± 75^a	160 ± 70^a	264^a
12 h	113 ± 162	181 ± 86^a	178 ± 78^a	208^a
18 h	121 ± 161	205 ± 210^a	203 ± 79^a	226^a
24 h	114 ± 163	210 ± 87^a	210 ± 93^a	204^a
Delta of urine NGAL (ng/ml)
0-3 h	13 ± 80	63 ± 42^a	62 ± 64^a	122^a
0-6 h	22 ± 104	89 ± 87^a	85 ± 86^a	166^a
0-12 h	49 ± 136	99 ± 91^a	103 ± 63^a	110^a
0-18 h	54 ± 131	124 ± 136^a	128 ± 55^a	128^a
0-24 h	46 ± 143	128 ± 136^a	135 ± 82^a	106^a
2C
Characteristic	CKD stage IV
	No CI-AKI	CI-AKI	CI-AKI (S1)	CI-AKI (S2)
	(N = 24)	(N = 6)	(N = 4)	(N = 2)
Serum creatinine (mg/dL)
Baseline	1.7 ± 0.5	2.4 ± 0.6^a	2.3 ± 0.6^a	2.5 ± 0.3^a
Follow-up (48 hr after)	1.6 ± 0.6	3.3 ± 1.3^a	2.9 ± 0.9^a	4.5 ± 0.6^a,b
Absolute change	-0.1 ± 0.3	1.0 ± 1.2^a	0.6 ± 0.4^a	2.1 ± 0.8^a,b
eGFR (ml/min)
Baseline	27 ± 3	20 ± 4^a	21 ± 5^a	19 ± 3^a
Follow-up (48 hr after)	27 ± 4	14 ± 6^a	15 ± 8^a	9 ± 4^a,b
Absolute change	0 ± 3	-7 ± 6^a	-6 ± 4^a	-10 ± 4^a,b
Urine NGAL (ng/ml)
Baseline	102 ± 98	217 ± 180^a	216 ± 231^a	218 ± 145^a
3 h	116 ± 157	314 ± 251^a	340 ± 318^a	261 ± 153^a
6 h	134 ± 162	404 ± 227^a	444 ± 280^a	324 ± 124^a
12 h	132 ± 191	409 ± 192^a	415 ± 239^a	396 ± 107^a
18 h	193 ± 230	394 ± 221^a	348 ± 226^a	349 ± 169^a
24 h	164 ± 182	385 ± 216^a	362 ± 131^a	329 ± 148^a
Delta of urine NGAL (ng/ml)
0-3 h	10 ± 156	97 ± 92^a	124 ± 106^a	84 ± 138^a
0-6 h	33 ± 131	187 ± 103^a	227 ± 101^a	217 ± 159^a
0-12 h	20 ± 227	192 ± 108^a	198 ± 108^a	248 ± 152^a
0-18 h	62 ± 186	112 ± 208^a	132 ± 112^a	162 ± 183^a,
0-24 h	63 ± 174	168 ± 212^a	145 ± 110^a	212 ± 192^a,

eGFR indicates estimated glomerular filtration rate.

^aP <0.05 compared with No-CI-AKI.

^bP <0.05 compared with CI-AKI (S1).